VolitionRx's (VNRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Jones Trading raised VolitionRx to a "strong-buy" rating and set a $3.00 price objective for the company in a report on Tuesday, June 10th. Wall Street Zen began coverage on shares of VolitionRx in a research note on Thursday, May 15th. They set a "sell" rating on the stock. Finally, HC Wainwright initiated coverage on shares of VolitionRx in a research report on Tuesday, April 8th. They set a "buy" rating and a $2.50 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, VolitionRx presently has an average rating of "Moderate Buy" and a consensus price target of $3.50.

VolitionRx Trading Down 1.8%

VNRX traded down $0.01 during trading on Wednesday, reaching $0.67. 73,707 shares of the company were exchanged, compared to its average volume of 206,737. The stock has a market cap of $69.43 million, a P/E ratio of -1.85 and a beta of 1.20. VolitionRx has a 52 week low of $0.40 and a 52 week high of $0.94. The firm has a 50 day moving average of $0.61 and a 200 day moving average of $0.58.

Hedge Funds Weigh In On VolitionRx

A number of hedge funds have recently modified their holdings of VNRX. Two Sigma Securities LLC purchased a new stake in VolitionRx during the fourth quarter valued at about $29,000. Millennium Management LLC acquired a new stake in shares of VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after purchasing an additional 60,209 shares during the period. Finally, Lagoda Investment Management L.P. grew its position in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.